Gujarat Themis Biosyn Acquires MicroBioPharm Japan for ₹1,351 Cr, Expands Global Footprint
Gujarat Themis Biosyn acquired MicroBioPharm Japan for ₹1,351 Cr, enhancing its global CDMO capabilities. MBJ reported FY26 revenue of ₹557 Cr and EBITDA of ₹138 Cr. The acquisition was funded via QIP and NCDs. Consolidated Q2 FY27 results show a ₹13.8 Cr PAT loss due to acquisition-related impacts.
The acquisition represents a major strategic shift, significantly expanding the company's operational scale, geographical reach, and service offerings in the global pharmaceutical market.
The acquisition of MicroBioPharm Japan is a significant strategic move expected to drive growth and expand the company's global presence and capabilities, despite short-term impacts on consolidated financials.
Gujarat Themis Biosyn Limited (GTBL) has announced the acquisition of MicroBioPharm Japan (MBJ) for a total consideration of ₹1,351 crore. This strategic move aims to enhance GTBL's fermentation capabilities, diversify its product portfolio into APIs, intermediates, and CDMO services, and establish a global platform leveraging MBJ's Japanese manufacturing base and established customer relationships.
The acquisition is expected to integrate GTBL's fermentation expertise with MBJ's technology, including precision fermentation, bio-conversion, and advanced development/manufacturing capabilities. MBJ brings three GMP-compliant manufacturing facilities in Japan, with a track record of FDA & PMDA approvals, and generated ₹557 crore in revenue in FY26.
GTBL's revenue breakup by segment for FY26 shows Contract Pharmaceuticals at 29.2%, Proprietary Pharmaceuticals at 34.2%, Non-Pharmaceuticals at 15.2%, Contract Pharmaceuticals (Bio) at 16.6%, Developed Pharmaceuticals (Bio) at 3.4%, and Developed Pharmaceuticals at 1.4%. The company highlights long-standing customer relationships, with its top 8 customers accounting for over 70% of revenue, and secured long-term supply contracts.
Financially, MBJ's yearly revenue was ₹557 crore in FY26, with EBITDA at ₹138 crore and an EBITDA margin of 25%. The purchase consideration of ₹1,351 crore was funded through QIP (₹727 crore), NCD India (₹493 crore), and NCD Singapore (₹131 crore). Additionally, ₹632 crore is being refinanced to repay MBJ's existing debt.
GTBL also provided quarterly financial highlights. Standalone revenue for Q2 FY27 was ₹48 crore, with PAT at ₹11 crore and EBITDA at ₹18 crore. Consolidated figures for Q2 FY27 show total income from operations at ₹49.9 crore, with a reported EBITDA loss of ₹0.9 crore and a PAT loss of ₹13.8 crore. This consolidated loss is attributed to one-time impacts including foreign exchange losses of ₹15.57 crore, partial-period consolidation of MBJ, and exceptional earthquake-related expenses of ₹1.2 crore at MBJ.
Looking ahead, GTBL plans to integrate and unlock synergies with MBJ, broaden its product and technology pipeline, expand global market access, and deliver sustainable, profitable growth. The company also highlighted its ongoing hybrid renewable power project, with 12.15 MW currently operational and a planned hybrid capacity of 18.45 MW by December 2026.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.